Both Yervoy and BMS' anti-PD-1 compounds came from Medarex.
The PD1 drugs will be the biggest blockbusters to come to oncology, perhaps ever.
I think the only criticism one can lay on Medarex management right now is that they sold out for a terribly low price considering the value PD1 will have in the future (although, shareholders made out well back then, I would assume...just not as much as they could have had they not sold the company)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.